FDA公布赛诺菲巴斯德马西莱图瓦勒疫苗厂483报告,列5项观察
FDA 483:赛诺菲巴斯德
FDA公布赛诺菲巴斯德位于法国马西莱图瓦勒的疫苗生产厂Form FDA 483,共列5项观察,检查日期为2023年9月18日至29日。观察涉及主批记录缺时限与指令、偏差调查缺结论与有效性核查、注射用水稀释液贮存条件不当、关键检验分析序列缺参考标准品,以及无菌区操作不符合无菌操作规范。文中提到Act-Hib美国市场一批因压盖后11,997支与目检11,996支的计数差异被判无效。
近日,FDA 公布了赛诺菲巴斯德(Sanofi Pasteur)位于法国里昂都会区马西莱图瓦勒(Marcy-l'Étoile)的疫苗生产厂(1541 Avenue Marcel Mérieux,FEI 3002972083)的483检查报告,列5项观察。
这家厂生产多款输美疫苗:Act-Hib(b型流感嗜血杆菌结合疫苗)、Typhim Vi(伤寒Vi多糖疫苗)、Imovax Rabies(人用狂犬病疫苗),以及配套的注射用水(WFI)稀释液。
5项观察依次是:主批记录缺时限与指令;偏差调查缺结论与有效性核查;成品贮存条件不当;关键检验的分析序列缺参考标准品;无菌区操作不符合无菌操作规范。其中一项的具体情节是:压盖后清点11,997支、目检11,996支,少了一支,整批被判无效。以下为原文与中文对照:
图 FDA 483 原件第1页(FEI 3002972083)
Inspection Details
检查基本信息
Firm / 企业
Sanofi Pasteur(赛诺菲巴斯德,赛诺菲集团疫苗事业部)
Address / 地址
1541 Avenue Marcel Mérieux, Marcy-l'Étoile, Métropole de Lyon, 69280, France
FEI Number / FEI 号
3002972083
Dates of Inspection / 检查日期
2023年9月18日–9月29日(原件加注:实际检查10天,9/18–9/22、9/25–9/29)
Type Establishment Inspected / 受检设施类型
Vaccine Manufacturer(疫苗生产企业)
Issued To / 收件人
Alain Denis,厂区负责人(Site Head)
Investigators / 检查员
Burnell M. Henry、Travis S. Bradly
District Office / 地区办公室
10903 New Hampshire Avenue, Bldg. 71, Rm 5054, Silver Spring, MD 20993-0002(电话 240-402-9160)
OBSERVATION 1
观察1:主批记录缺完整指令
The master production and control records are deficient in that they do not include complete instructions.
主生产及控制记录存在缺陷,未包含完整的指令。
Specifically, there are no defined (b)(4) time frames and/or instructions for the (b)(4) preparation of the Concentrated Tetanus Protein (CTP) bulk in the Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) manufacturing process.
具体而言,在b型流感嗜血杆菌结合疫苗(破伤风类毒素结合)生产工艺中,对浓缩破伤风蛋白(CTP)原液的(b)(4)制备,既未规定(b)(4)时限,也没有相应指令。
A. The CTP bulk requires the (b)(4) of the bulk after the (b)(4) step in Bldg. (b)(4) (Room (b)(4)). The (b)(4) system is rinsed with a (b)(4) solution and collected into (b)(4) individual (b)(4) (b)(4) that are (b)(4) into a (b)(4) container, (b)(4) the CTP (b)(4) process. The CTP bulk is (b)(4) by the technician (b)(4) the (b)(4) container in a (b)(4) (b)(4) for an unknown specified amount of time under the biosafety cabinet. A bioburden sample is taken at this step at this step, (b)(4) the CTP bulk (b)(4) process.
A. CTP原液在(b)(4)栋((b)(4)房间)完成(b)(4)步骤后,需要对该原液进行(b)(4)。(b)(4)系统用(b)(4)溶液冲洗,收集到(b)(4)个单独的(b)(4)(b)(4)中,再(b)(4)到一个(b)(4)容器内,(b)(4)CTP的(b)(4)过程。技术员在生物安全柜下将CTP原液(b)(4)、(b)(4)该(b)(4)容器,放入一个(b)(4)(b)(4),放置“一段未指明的时长”。该步骤取生物负载样品,(b)(4)CTP原液的(b)(4)过程。
B. The production batch record does not include instructions for the (b)(4) steps for the CTP bulk, (b)(4).
B. 生产批记录未包含CTP原液(b)(4)步骤的指令,(b)(4)。
C. There is no validated mixing time-frame established for the CTP bulk concentration (b)(4) step to ensure (b)(4).
C. CTP原液浓缩的(b)(4)步骤,未建立经验证的混合时限,无法确保(b)(4)。
OBSERVATION 2
观察2:调查缺结论、缺有效性核查
Written records of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications do not always include the conclusions and follow-up.
对无法解释的差异,以及批次或其任何组分不符合标准的调查,其书面记录并不总是包含结论与后续跟进。
Specifically,
具体而言:
A. Deviation record MLED22E3775 dated August 1, 2022, documents that two vials of (b)(4) (US Market batch (b)(4)) were observed to contain cellulose particles during visual inspection of retain samples related to a complaint of vial breakage (complaint no. 200255622). This lot had been released and distributed within the US market and was reported to the agency as a Biological Product Deviation Report (BPDR) on 09/15/2022. While reviewing the firm's CAPA investigation report MLED22A2877 pertaining to deviation MLED22E3775, it was observed that no effectiveness check was conducted to verify the effectiveness of the corrective action (updating instruction MLE-1-006038—clarifying the practice of the cutting of bags within filling line 14) implemented in response to the deviation.
A. 2022年8月1日的偏差记录 MLED22E3775 记载:在处理一起西林瓶破损投诉(投诉号 200255622)时,对留样做目视检查,发现(b)(4)(美国市场批(b)(4))中有两支西林瓶含纤维素颗粒。该批此前已放行并在美国市场销售,企业已于2022年9月15日以生物制品偏差报告(BPDR)上报FDA。审阅企业就该偏差所做的CAPA调查报告 MLED22A2877 时发现:针对该偏差采取的纠正措施(更新指令 MLE-1-006038,澄清14号灌装线内裁切袋子的做法)未做有效性核查,无从确认其是否真的有效。
B. While reviewing (b)(4) batch number (b)(4) (b)(4) (b)(4) for line (b)(4) utilized at the time for sterile (b)(4) of Act-Hib (US Market), it was observed that the (b)(4) batch was invalidated due to a reconciliation difference between the quantity of crimped vials (11,997) and the quantity of inspected vials (11,996) prior to being sent for (b)(4). Further review into the investigation of the discrepancy (Deviation MLED21E6490) revealed that the discrepancy was likely the result of a lost vial after the crimping step during transfer to visual inspection (b)(4). Due to the vial being lost, it could not be incubated and read for turbidity resulting in a potential impact to product manufactured on line (b)(4). While reviewing the firm's corrective actions pertaining to the deviation, it was observed that no corrective actions were implemented to prevent a recurrence of this event.
B. 审阅(b)(4)批号(b)(4)的(b)(4)记录时——该批当时用于 Act-Hib(美国市场)的无菌(b)(4),线号(b)(4)——发现该(b)(4)批因数量对不上而被判无效:压盖后的西林瓶为11,997支,送去做(b)(4)之前目检的西林瓶为11,996支。进一步审阅该差异的调查(偏差 MLED21E6490)显示,差异很可能是压盖步骤之后、转往目检(b)(4)途中丢失了一支瓶所致。因该瓶丢失,无法对其培养并读取浊度,对(b)(4)线上生产的产品构成潜在影响。审阅企业就该偏差采取的纠正措施时发现:未实施任何纠正措施以防止此类事件再次发生。
OBSERVATION 3
观察3:贮存条件不当(注射用水稀释液)
Drug products are not stored under appropriate conditions so that their identity, strength, quality, and purity are not affected.
药品未在适当条件下贮存,无法保证其鉴别、含量、质量与纯度不受影响。
While observing warehousing operations within temperature controlled (2-8C) finished product storage room (b)(4) within the packaging warehouse, it was observed that one shrink wrapped pallet consisting of (b)(4) boxes ((b)(4) (b)(4)) of WFI diluent batch (b)(4) were not stored under appropriate conditions to prevent potential contamination of the product. It was observed that (b)(4) box lids covering the extra WFI diluent finished product (b)(4) were dislodged and not attached to the boxes potentially exposing the (b)(4) to the environment. Additionally, this (b)(4) was observed to be stored below a (b)(4) unit located within the storage room. Per the firm's Packaging Production Manager, these doses can be distributed and utilized with any lyophilized product the firm manufactures (US and ROW Markets).
在包装仓库内温控(2–8℃)成品贮存间(b)(4)巡查仓储作业时,发现一个热缩膜包裹的托盘,装着(b)(4)箱((b)(4))注射用水(WFI)稀释液批(b)(4),未按规定条件贮存,无法防止产品受到潜在污染。覆盖在这些多余的WFI稀释液成品(b)(4)上的(b)(4)箱盖已脱落、未扣在箱子上,可能使(b)(4)暴露于环境。此外,该(b)(4)存放在贮存间内一台(b)(4)装置的下方。据企业包装生产经理称,这些剂量可随公司生产的任何冻干产品一起分销和使用(美国及ROW市场)。
OBSERVATION 4
观察4:分析序列未纳入参考标准品
Laboratory controls do not include the establishment of scientifically sound and appropriate standards designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity.
实验室控制未包含建立科学合理且适当的标准,以确保药品符合鉴别、含量、质量与纯度方面的适当标准。
Specifically, reference standards are not included in analytical sequences to verify (b)(4) control for the following critical test assays.
具体而言,下列关键检验项目的分析序列中,未纳入参考标准品以确证(b)(4)的控制。
A. SOP: MLE.I-005714, titled, (b)(4). A blank is analyzed at the beginning of the (b)(4) method analysis (b)(4) the sample analysis. The (b)(4) absorbance sample result is used for the Purified Vi Polysaccharide bulk (Typhoid Vaccine) (b)(4) content final release assay.
A. SOP:MLE.I-005714,标题为(b)(4)。在(b)(4)方法分析开始时先分析一个空白,(b)(4)样品分析。(b)(4)吸光度样品结果,用于纯化Vi多糖原液(伤寒疫苗)(b)(4)含量的最终放行检验。
B. SOP: Qu-WIN-0040813, titled, "V16 (b)(4) Use of (b)(4) in Rooms (b)(4) and (b)(4)," - A blank is analyzed (b)(4) method analysis (b)(4) (b)(4) individual (b)(4) samples are analyzed. An average of the (b)(4) readings are used for the (b)(4) measurement. The (b)(4) is measured at the (b)(4) steps during the (b)(4) of the Vi Polysaccharide (Typhim Vi Vaccine) manufacturing process to (b)(4) for further processing. These steps are identified as critical processing parameters (CPP) in the manufacturing process.
B. SOP:Qu-WIN-0040813,标题为“V16 (b)(4) 在(b)(4)与(b)(4)房间的使用”。分析时先分析一个空白,(b)(4)方法分析(b)(4)个单独的(b)(4)样品。取(b)(4)读数的平均值用于(b)(4)测定。该(b)(4)在Vi多糖(Typhim Vi疫苗)生产工艺的(b)(4)步骤测定,用于判定是否进入后续加工。这些步骤在生产工艺中被识别为关键工艺参数(CPP)。
OBSERVATION 5
观察5:无菌操作未按规范执行
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
为防止声称无菌的药品受到微生物污染而设计的程序,未被遵守。
Specifically, While observing sterile (b)(4) operations for Imovax Rabies batch X1C16 (US Market) on (b)(4) line (b)(4) within the (b)(4) manufacturing building on September 25, 2023, it was observed that (b)(4) operators observed within the Grade (b)(4) supporting area on the (b)(4) line (directly outside the (b)(4)) did not utilize aseptic best practices to limit disruption of (b)(4). It was observed that (b)(4) operators were routinely swaying their hands by their sides while walking throughout the supporting area during (b)(4) in a non-deliberate manner.
具体而言,2023年9月25日,在(b)(4)生产楼内(b)(4)线的(b)(4)区域,观察 Imovax Rabies(人用狂犬病疫苗)批号 X1C16(美国市场)的无菌(b)(4)操作时发现:(b)(4)线上 Grade (b)(4) 支持区(紧邻(b)(4)外侧)内的(b)(4)操作人员,未采用无菌操作最佳规范来限制对(b)(4)的干扰。观察到操作人员在支持区内走动时,双手习惯性地在身体两侧摆动,且属非故意动作。
Notes
译注
① 企业名:Sanofi Pasteur 中文通称“赛诺菲巴斯德”,为赛诺菲集团疫苗事业部。受检厂区位于法国里昂都会区马西莱图瓦勒,是赛诺菲全球疫苗研发与生产基地之一。收件人 Alain Denis 的职务为厂区负责人(Site Head)。
② 产品:Act-Hib 为b型流感嗜血杆菌(Hib)结合疫苗(破伤风类毒素结合);Typhim Vi 为伤寒Vi多糖疫苗;Imovax Rabies 为人用狂犬病疫苗;WFI diluent 为注射用水稀释液,用于复溶冻干制剂。“ROW”为 Rest of World 的缩写,指美国以外的其他市场。
③ 原文观察1 A 项末句“A bioburden sample is taken at this step at this step”重复了“at this step”,系原件如此,照录未改。
④ 原件为格式化表格,未印 21 CFR 条款号,本稿不代为标注。第1–4页为观察项,第5页为表格背面,内容为 21 U.S.C. 374(b)(《联邦食品、药品和化妆品法案》第704(b)条)的标准条文,非观察项,未译。
⑤ 原文中“(b)(4)”为 FDA 依《信息自由法》对商业秘密与保密信息的遮蔽标记;本稿按原位置照录,不补写被遮蔽内容。被遮蔽较多处,中文对照读起来会显得断续,这是原件状态。
来源:制药经理人 · mp.weixin.qq.com